Ghost Tree Capital’s Moderna MRNA Stock Holding History

Ghost Tree Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-35,000	Closed	-$3.66M	–	53
2020 Q4	$3.66M	Buy	+35,000	New	+$3.54M	0.81%	33

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ghost Tree Capital's MRNA Position: Q4 2021 in Review

Ghost Tree Capital sold out of Moderna (MRNA) in Q4 2021, closing a stake of 5,300 shares — an estimated $2.04M sold.

Ghost Tree Capital first reported a position in MRNA in Q2 2020 and held it in 4 quarters. The position peaked at $2.04M in Q3 2021. 1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

Ghost Tree Capital reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
Ghost Tree Capital sold 5,300 Moderna shares in Q4 2021, an estimated $2.04M.
Ghost Tree Capital first reported a position in Moderna in Q2 2020 and held it in 4 quarters.
Ghost Tree Capital's Moderna position peaked at $2.04M in Q3 2021.
1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Ghost Tree Capital's 13F filing for Q4 2021, filed 16 Feb 2022.